Relevant bibliographies by topics / Drug delivery in cancer therapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Drug delivery in cancer therapy'

Author: Grafiati
Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug delivery in cancer therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug delivery in cancer therapy"

1

SL, Prabu. "Nano based Drug Delivery System for Cancer Therapy: A Next Generation Theranostics." Bioequivalence & Bioavailability International Journal 6, no. 2 (July 15, 2022): 1–17. http://dx.doi.org/10.23880/beba-16000178.

Full text
Abstract:
Cancer is considered as one of the foremost cause of illness and death with very complex pathophysiology even though prominent advancement has been made on innovative tumor treatments. Therapeutic properties and the global survival rate are still disappointing for the patients with cancer. There is a shortfall in the capabilities of these cancer therapies, some novel strategies are developed to provide better treatment therapies to improve their quality of life and also aids in reducing the number of deaths. Amongst the cardinal phases towards ensuring ideal cancer management is early diagnosis and targeted drug delivery of anti-tumor to decrease its toxicities. Recently the progress of nanotechnology as novel therapeutics, have advanced and trialed to overwhelm numerous limitations of previously available drug delivery systems for cancer treatment. Nanobased therapeutics has provided the chance to directly contact the tumorous cells selectively with improved drug localization, cellular application as well as providing targeted drug delivery eluding the interaction with the healthy cells. In this review, we summarize about various novel nanomaterials as anti-tumour drug delivery carriers for cancer treatment; also provide insight into the superlative necessities of nanotechnology in cancer therapy and its challenges in targeted drug delivery
APA, Harvard, Vancouver, ISO, and other styles
2

Yadav, Neena, Arul Prakash Francis, Veeraraghavan Vishnu Priya, Shankargouda Patil, Shazia Mustaq, Sameer Saeed Khan, Khalid J. Alzahrani, et al. "Polysaccharide-Drug Conjugates: A Tool for Enhanced Cancer Therapy." Polymers 14, no. 5 (February 27, 2022): 950. http://dx.doi.org/10.3390/polym14050950.

Full text
Abstract:
Cancer is one of the most widespread deadly diseases, following cardiovascular disease, worldwide. Chemotherapy is widely used in combination with surgery, hormone and radiation therapy to treat various cancers. However, chemotherapeutic drugs can cause severe side effects due to non-specific targeting, poor bioavailability, low therapeutic indices, and high dose requirements. Several drug carriers successfully overcome these issues and deliver drugs to the desired sites, reducing the side effects. Among various drug delivery systems, polysaccharide-based carriers that target only the cancer cells have been developed to overcome the toxicity of chemotherapeutics. Polysaccharides are non-toxic, biodegradable, hydrophilic biopolymers that can be easily modified chemically to improve the bioavailability and stability for delivering therapeutics into cancer tissues. Different polysaccharides, such as chitosan, alginates, cyclodextrin, pullulan, hyaluronic acid, dextran, guar gum, pectin, and cellulose, have been used in anti-cancer drug delivery systems. This review highlights the recent progress made in polysaccharides-based drug carriers in anti-cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Anitha, P., J. Bhargavi, G. Sravani, B. Aruna, and Ramkanth S. "RECENT PROGRESS OF DENDRIMERS IN DRUG DELIVERY FOR CANCER THERAPY." International Journal of Applied Pharmaceutics 10, no. 5 (September 8, 2018): 34. http://dx.doi.org/10.22159/ijap.2018v10i5.27075.

Full text
Abstract:
With the recent advances of nanotechnology, dendrimers are emerging as a highly attractive class of drug delivery vectors for cancer therapy. Dendrimers are multifunctional smart Nanocarriers to deliver one or more therapeutic agent safely and selectively to cancer cells. The high level of control over the synthesis of dendritic architecture makes dendrimers a nearly perfect (spherical) nanocarrier for site-specific drug delivery. The presence of functional groups in the dendrimers exterior also permits the addition of other moieties that can actively target certain diseases which are now widely used as tumor targeting strategies. Drug encapsulation, solubilization and passive targeting also equally contribute to the therapeutic use of dendrimers. Dendrimers are ideal carrier vehicles on cytotoxicity, blood plasma retention time, biodistribution and tumor uptake. In this review we highlight the advantages of dendrimers over conventional chemotherapy, toxicity and its management, following anti-cancer drugs delivered by using dendrimers and recent advances in drug delivery by various types of dendrimers as well as its diagnostic applications.
APA, Harvard, Vancouver, ISO, and other styles
4

Vasir, Jaspreet K., and Vinod Labhasetwar. "Targeted Drug Delivery in Cancer Therapy." Technology in Cancer Research & Treatment 4, no. 4 (August 2005): 363–74. http://dx.doi.org/10.1177/153303460500400405.

Full text
Abstract:
Chemotherapy has been the main modality of treatment for cancer patients; however, its success rate remains low, primarily due to limited accessibility of drugs to the tumor tissue, their intolerable toxicity, development of multi-drug resistance, and the dynamic heterogeneous biology of the growing tumors. Better understanding of tumor biology in recent years and new targeted drug delivery approaches that are being explored using different nanosystems and bioconjugates provide optimism in developing successful cancer therapy. This article reviews the possibilities and challenges for targeted drug delivery in cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
5

Subhan, Md Abdus, and Vladimir P. Torchilin. "Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate." Pharmaceutics 15, no. 4 (April 14, 2023): 1242. http://dx.doi.org/10.3390/pharmaceutics15041242.

Full text
Abstract:
Antibody–drug conjugates (ADCs) are a potential and promising therapy for a wide variety of cancers, including breast cancer. ADC-based drugs represent a rapidly growing field of breast cancer therapy. Various ADC drug therapies have progressed over the past decade and have generated diverse opportunities for designing of state-of-the-art ADCs. Clinical progress with ADCs for the targeted therapy of breast cancer have shown promise. Off-target toxicities and drug resistance to ADC-based therapy have hampered effective therapy development due to the intracellular mechanism of action and limited antigen expression on breast tumors. However, innovative non-internalizing ADCs targeting the tumor microenvironment (TME) component and extracellular payload delivery mechanisms have led to reduced drug resistance and enhanced ADC effectiveness. Novel ADC drugs may deliver potent cytotoxic agents to breast tumor cells with reduced off-target effects, which may overcome difficulties related to delivery efficiency and enhance the therapeutic efficacy of cytotoxic cancer drugs for breast cancer therapy. This review discusses the development of ADC-based targeted breast cancer therapy and the clinical translation of ADC drugs for breast cancer treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

Yu, Han, Na Ning, Xi Meng, Chuda Chittasupho, Lingling Jiang, and Yunqi Zhao. "Sequential Drug Delivery in Targeted Cancer Therapy." Pharmaceutics 14, no. 3 (March 5, 2022): 573. http://dx.doi.org/10.3390/pharmaceutics14030573.

Full text
Abstract:
Cancer is a major public health problem and one of the leading causes of death. However, traditional cancer therapy may damage normal cells and cause side effects. Many targeted drug delivery platforms have been developed to overcome the limitations of the free form of therapeutics and biological barriers. The commonly used cancer cell surface targets are CD44, matrix metalloproteinase-2, folate receptors, etc. Once the drug enters the cell, active delivery of the drug molecule to its final destination is still preferred. The subcellular targeting strategies include using glucocorticoid receptors for nuclear targeting, negative mitochondrial membrane potential and N-acetylgalactosaminyltransferase for Golgi apparatus targeting, etc. Therefore, the most effective way to deliver therapeutic agents is through a sequential drug delivery system that simultaneously achieves cellular- and subcellular-level targeting. The dual-targeting delivery holds great promise for improving therapeutic effects and overcoming drug resistance. This review classifies sequential drug delivery systems based on final targeted organelles. We summarize different targeting strategies and mechanisms and gave examples of each case.
APA, Harvard, Vancouver, ISO, and other styles
7

Sayyed, Adil A., Piyush Gondaliya, Palak Bhat, Mukund Mali, Neha Arya, Amit Khairnar, and Kiran Kalia. "Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update." Current Pharmaceutical Design 28, no. 6 (February 2022): 471–87. http://dx.doi.org/10.2174/1381612827666211109113305.

Full text
Abstract:
: The discovery of microRNAs (miRNAs) has been one of the revolutionary developments and has led to the advent of new diagnostic and therapeutic opportunities for the management of cancer. In this regard, miRNA dysregulation has been shown to play a critical role in various stages of tumorigenesis, including tumor invasion, metastasis as well as angiogenesis. Therefore, miRNA profiling can provide accurate fingerprints for the development of diagnostic and therapeutic platforms. This review discusses the recent discoveries of miRNA- based tools for early detection of cancer as well as disease monitoring in cancers that are common, like breast, lung, hepatic, colorectal, oral and brain cancer. Based on the involvement of miRNA in different cancers as oncogenic miRNA or tumor suppressor miRNA, the treatment with miRNA inhibitors or mimics is recommended. However, the stability and targeted delivery of miRNA remain the major limitations of miRNA delivery. In relation to this, several nanoparticle-based delivery systems have been reported which have effectively delivered the miRNA mimics or inhibitors and showed the potential for transforming these advanced delivery systems from bench to bedside in the treatment of cancer metastasis and chemoresistance. Based on this, we attempted to uncover recently reported advanced nanotherapeutic approaches to deliver the miRNAs in the management of different cancers.
APA, Harvard, Vancouver, ISO, and other styles
8

Li, Jiayao, Yinan Liu, and Hend Abdelhakim. "Drug Delivery Applications of Coaxial Electrospun Nanofibres in Cancer Therapy." Molecules 27, no. 6 (March 10, 2022): 1803. http://dx.doi.org/10.3390/molecules27061803.

Full text
Abstract:
Cancer is one of the most serious health problems and the second leading cause of death worldwide, and with an ageing and growing population, problems related to cancer will continue. In the battle against cancer, many therapies and anticancer drugs have been developed. Chemotherapy and relevant drugs are widely used in clinical practice; however, their applications are always accompanied by severe side effects. In recent years, the drug delivery system has been improved by nanotechnology to reduce the adverse effects of the delivered drugs. Among the different candidates, core–sheath nanofibres prepared by coaxial electrospinning are outstanding due to their unique properties, including their large surface area, high encapsulation efficiency, good mechanical property, multidrug loading capacity, and ability to govern drug release kinetics. Therefore, encapsulating drugs in coaxial electrospun nanofibres is a desirable method for controlled and sustained drug release. This review summarises the drug delivery applications of coaxial electrospun nanofibres with different structures and drugs for various cancer treatments.
APA, Harvard, Vancouver, ISO, and other styles
9

Montané, Xavier, Anna Bajek, Krzysztof Roszkowski, Josep M. Montornés, Marta Giamberini, Szymon Roszkowski, Oliwia Kowalczyk, Ricard Garcia-Valls, and Bartosz Tylkowski. "Encapsulation for Cancer Therapy." Molecules 25, no. 7 (March 31, 2020): 1605. http://dx.doi.org/10.3390/molecules25071605.

Full text
Abstract:
The current rapid advancement of numerous nanotechnology tools is being employed in treatment of many terminal diseases such as cancer. Nanocapsules (NCs) containing an anti-cancer drug offer a very promising alternative to conventional treatments, mostly due to their targeted delivery and precise action, and thereby they can be used in distinct applications: as biosensors or in medical imaging, allowing for cancer detection as well as agents/carriers in targeted drug delivery. The possibility of using different systems—inorganic nanoparticles, dendrimers, proteins, polymeric micelles, liposomes, carbon nanotubes (CNTs), quantum dots (QDs), biopolymeric nanoparticles and their combinations—offers multiple benefits to early cancer detection as well as controlled drug delivery to specific locations. This review focused on the key and recent progress in the encapsulation of anticancer drugs that include methods of preparation, drug loading and drug release mechanism on the presented nanosystems. Furthermore, the future directions in applications of various nanoparticles are highlighted.
APA, Harvard, Vancouver, ISO, and other styles
10

Shakil, Md Salman, Kazi Mustafa Mahmud, Mohammad Sayem, Mahruba Sultana Niloy, Sajal Kumar Halder, Md Sakib Hossen, Md Forhad Uddin, and Md Ashraful Hasan. "Using Chitosan or Chitosan Derivatives in Cancer Therapy." Polysaccharides 2, no. 4 (October 13, 2021): 795–816. http://dx.doi.org/10.3390/polysaccharides2040048.

Full text
Abstract:
Cancer is one of the major causes of death worldwide. Chemotherapeutic drugs have become a popular choice as anticancer agents. Despite the therapeutic benefits of chemotherapeutic drugs, patients often experience side effects and drug resistance. Biopolymers could be used to overcome some of the limitations of chemotherapeutic drugs, as well as be used either as anticancer agents or drug delivery vehicles. Chitosan is a biocompatible polymer derived from chitin. Chitosan, chitosan derivatives, or chitosan nanoparticles have shown their promise as an anticancer agent. Additionally, functionally modified chitosan can be used to deliver nucleic acids, chemotherapeutic drugs, and anticancer agents. More importantly, chitosan-based drug delivery systems improved the efficacy, potency, cytotoxicity, or biocompatibility of these anticancer agents. In this review, we will investigate the properties of chitosan and chemically tuned chitosan derivatives, and their application in cancer therapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug delivery in cancer therapy"

1

Yung, Bryant Chinung. "NANOPARTICLE DRUG DELIVERY SYSTEMS FOR CANCER THERAPY." The Ohio State University, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=osu1417614665.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zi, Hong. "Polymers for drug delivery in cancer therapy /." May be available electronically:, 2008. http://proquest.umi.com/login?COPT=REJTPTU1MTUmSU5UPTAmVkVSPTI=&clientId=12498.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Liu, Yang. "Development of Novel Drug Delivery Systems for Cancer Therapy." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu153105342400785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Xu, Leyuan. "Engineering of Polyamidoamine Dendrimers for Cancer Therapy." VCU Scholars Compass, 2015. http://scholarscompass.vcu.edu/etd/3773.

Full text
Abstract:
Dendrimers are a class of polymers with a highly branched, three-dimensional architecture comprised of an initiator core, several interior layers of repeating units, and multiple active surface terminal groups. Dendrimers have been recognized as the most versatile compositionally and structurally controlled nanoscale building blocks for drug and gene delivery. Polyamidoamine (PAMAM) dendrimers have been most investigated because of their unique structures and properties. Polycationic PAMAM dendrimers form compacted polyplexes with nucleic acids at physiological pH, holding great potential for gene delivery. Folate receptor (FRα) is expressed at very low levels in normal tissues but expressed at high levels in cancers in order to meet the folate demand of rapidly dividing cells under low folate conditions. Our primary aim was to investigate folic acid (FA)-conjugated PAMAM dendrimer generation 4 (G4) conjugates (G4-FA) for targeted gene delivery. The in vitro cellular uptake and transfection efficiency of G4-FA conjugates and G4-FA/DNA polyplexes were investigated in Chapter 4. It was found the cellular uptake of G4-FA conjugates and G4-FA/DNA polyplexes was in a FR-dependent manner. Free FA competitively inhibited the cellular uptake of G4-FA conjugates and G4-FA/DNA polyplexes. G4-FA/DNA polyplexes were preferentially taken up by FR-positive HN12 cells but not FR-negative U87 cells. In contrast, the cellular uptake of G4 dendrimers and G4/DNA polyplexes was non-selective via absorptive endocytosis. G4-FA conjugates significantly enhanced cytocompatibility and transfection efficiency compared to G4 dendrimers. This work demonstrates that G4-FA conjugates allow FR-targeted gene delivery, reduce cytotoxicity, and enhance gene transfection efficiency. The in vivo biodistribution of G4-FA conjugates and anticancer efficacy of G4-FA/siRNA polyplexes were investigated in Chapter 5. Vascular endothelial growth factor A (VEGFA) is one of the major regulators of angiogenesis, essential for the tumor development. It was found G4-FA/siVEGFA polyplexes significantly knocked down VEGFA mRNA expression and protein release in HN12 cells. In the HN12 tumor-bearing nude mice, G4-FA conjugates were preferentially taken up by the tumor and retained in the tumor for at least 21 days following intratumoral (i.t.) administration. Two-dose i.t. administration of G4-FA/siVEGFA polyplexes significantly inhibited tumor growth by lowering tumor angiogenesis. In contrast, two-dose i.t. administration of G4/siVEGFA polyplexes caused severe skin lesion, presumably as a result of local toxicity. Taken together, this work shows great potential for the use of G4-FA conjugates in targeted gene delivery and cancer gene therapy. We also explored polyanionic PAMAM dendrimer G4.5 as the underlying carrier to carry camptothecin (CPT) for glioblastoma multiforme therapyin Chapter 6. "Click" chemistry was applied to improve polymer-drug coupling reaction efficiency. The CPT-conjugate displayed a dose-dependent toxicity with an IC50 of 5 μM, a 185-fold increase relative to free CPT, presumably as a result of slow release. The conjugated CPT resulted in G2/M arrest and cell death while the dendrimer itself had little to no toxicity. This work indicates highly efficient "click" chemistry allows for the synthesis of multifunctional dendrimers for sustained drug delivery. Immobilizing PAMAM dendrimers to the cell surface may represent an innovative method of enhancing cell surface loading capacity to deliver therapeutic and imaging agents. In Chapter 7, macrophage RAW264.7 (RAW) was hybridized with PAMAM dendrimer G4.0 (DEN) on the basis of bioorthogonal chemistry. Efficient and selective cell surface immobilization of dendrimers was confirmed by confocal microscopy. It was found the viability and motility of RAW-DEN hybrids remained the same as untreated RAW cells. Furthermore, azido sugar and dendrimer treatment showed no effect on intracellular AKT, p38, and NFκB (p65) signaling, indicating that the hybridization process neither induced cell stress response nor altered normal signaling. This work shows the feasibility of applying bioorthogonal chemistry to create cell-nanoparticle hybrids and demonstrates the noninvasiveness of this cell surface engineering approach. In summary, these studies indicate surface-modification of PAMAM dendrimer G4 with FA can effectively target at FR-positive cells and subsequently enhance in vitro transfection efficiency and in vivo gene delivery. G4-FA conjugates may serve as a versatile targeted gene delivery carrier potentially for cancer gene therapy. PAMAM dendrimers G4.5 may serve as a drug delivery carrier for the controlled release of chemotherapeutics. The immune cell-dendrimer hybrids via bioorthogonal chemistry may serve as an innovative drug and gene delivery carrier potentially for cancer chemotherapy. Taken together, engineering of PAMAM dendrimers may advance anticancer drug and gene delivery.
APA, Harvard, Vancouver, ISO, and other styles
5

Qin, Yiru. "Graphene Quantum Dots-Based Drug Delivery for Ovarian Cancer Therapy." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6358.

Full text
Abstract:
Ovarian cancer, one of the most dreadful malignancies of the female reproductive system, poses a lethal threat to women worldwide. In this dissertation, the objective was to introduce a novel type of graphene quantum dots (GQDs) based nano-sized drug delivery systems (DDS) for ovarian cancer treatment. As a starting point, the facile synthesis method of the GQDs was established. Subsequently, the targeting ligand,folic acid (FA), was conjugated to GQDs. Next, a FDA approved chemotherapeutic drug, Doxorubicin (DOX), was loaded to form the GQDs-FA-DOX nano-conjugation as the DDS. Moreover, the uptake profile and anti-cancer effect of the GQDs-FA-DOX were validated in ovarian cancer cells. Finally, the immunotoxicity of GQDs and its mechanism were investigated and elucidated. Taken together, the findings described in this dissertation provide a novel and powerful strategy of targeted treatment for ovarian cancer.
APA, Harvard, Vancouver, ISO, and other styles
6

Man, Kwun-wai Dede, and 文冠慧. "Oleanolic acid delivery using biodegradable nanoparticles for cancer therapy." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2015. http://hdl.handle.net/10722/208550.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Escolà, Jané Anna. "Somatostatin analogues as drug delivery systems for receptor-targeted cancer therapy." Doctoral thesis, Universitat de Barcelona, 2018. http://hdl.handle.net/10803/663804.

Full text
Abstract:
Somatostatin (SST or SRIF14) is a peptidic hormone secreted throughout the central nervous system and in the gastrointestinal tract which has anti-secretory, anti-proliferative and anti-angiogenic effects. Although its administration as a drug is effective in certain conditions, its therapeutic use is limited by its short plasma half-life (< 3 min), the broad spectrum of biological responses and the lack of selectivity over its receptors (SSTRs). In order to obtain more stable and selective analogues we have incorporated both non-natural electron-rich and electron-poor aromatic amino acids at key positions of the native sequence to overcome the above-mentioned drawbacks. In this regard, we have obtained different analogues which have been studied by NMR obtaining the structures of the major set of conformations. Their binding profile and half-lives have also been determined. Among all the analogues, one stood out due to its half-life of around 40 h, the highest one known for a SRIF14 analogue. Furthermore, it displayed a major set of conformations in solution and high selectivity towards SSTR2. In recent years, receptor-targeted cancer therapy has gained interest as certain receptors are overexpressed in cancer cells. This is the case of SSTRs in endocrine tumours. On this subject, we have coupled different molecules at the N-terminal part of the previously mentioned analogue. The first one was a chromophore which enabled us to follow the internalisation of the analogue inside CHO-K1 wild type (WT) and CHO-K1 SSTR2-overexpressing (ST) cell lines which turned to be far more better in ST than in WT. In light of these findings, we decided to go one step further and test this analogue as a drug delivery system thus coupling it to a colour-changing chromophore (green: bonded to the peptide, blue: when released). As before, both the internalisation and the drug release was better in ST than in WT. Last step was to test the analogue as a p38α inhibitor by coupling the inhibitor directly at the N-terminal part. As for the other assays, the inhibition of p-Hsp27 (p38α downstream target) was better in ST than in WT which was attributed to a better internalisation of the analogue.
La somatostatina (SST o SRIF14) es una hormona peptídica secretada por el sistema nervioso central y el tracto gastrointestinal que tiene efectos anti-secretores, anti-proliferativos y anti-angiogénicos. Aunque su administración como fármaco es eficaz en ciertas condiciones, su uso terapéutico está limitado por su corta vida media plasmática (<3 min), el amplio espectro de respuestas biológicas y la falta de selectividad entre sus receptores. Con el fin de obtener análogos más estables y selectivos, hemos incorporado aminoácidos aromáticos no naturales ricos y pobres en electrones en posiciones clave de la secuencia nativa para superar dichos inconvenientes. Así, se obtuvieron diferentes análogos que fueron estudiados por RMN obteniendo la estructura de sus conformaciones mayoritarias. También se determinó su perfil de unión a los receptores y sus vidas medias. Entre los análogos, uno destacó por tener una vida media de 40 h, la más alta conocida para un análogo de 14 aminoácidos. Además, mostró un conjunto de conformaciones en solución parecido y una gran selectividad para SSTR2. Recientemente, la terapia contra el cáncer dirigida a receptores ha ganado interés ya que ciertos receptores están sobre-expresados en las células cancerosas. Este es el caso de los receptores de somatostatina en tumores endocrinos. Así, acoplamos diferentes moléculas en la parte N-terminal del análogo mencionado anteriormente. La primera fue un cromóforo que nos permitió seguir la internalización del análogo en dos líneas celulares: CHO-K1 de tipo salvaje (WT) y CHO-K1 con SSTR2 sobre-expresado (ST); dicha internalización fue mucho mejor en ST que en WT. Al ver estos resultados prometedores, fuimos un paso más allá y probamos el análogo cómo sistema de liberación de fármacos, acoplándolo a un cromóforo que cambia de color (verde: unido al péptido, azul: cuando se libera). Cómo antes, tanto la internalización como la liberación fueron mejores en ST que en WT. El último paso fue probar el análogo como inhibidor de p38α acoplando el inhibidor directamente en la parte N-terminal. Cómo en los ensayos anteriores, la inhibición de p-Hsp27 (diana downstream de p38α) fue mejor en ST que en WT, lo que se atribuyó a una mejor internalización del análogo en ST.
APA, Harvard, Vancouver, ISO, and other styles
8

Riaz, Muhammad Kashif. "Peptide functionalized drug delivery system for an efficient lung cancer therapy." HKBU Institutional Repository, 2019. https://repository.hkbu.edu.hk/etd_oa/609.

Full text
Abstract:
Lung cancer has a high incidence rate globally and the leading cause of cancer related mortalities. In 2018, lung cancer has been estimated to cause 1.76 million deaths worldwide (18.33% of total cancer mortalities). In Hong Kong lung cancer has been a leading cause of cancer related deaths, and in 2016 caused 3780 deaths (26.6% of total cancer mortalities). Non-small cell lung cancer (NSCLC) is the major (~85%) lung cancer type, and five-year survival rate for lung cancer has estimated to be 18%. Thus, an efficient lung cancer treatment with lesser adverse effects is need of the hour. In this connection, active targeting of overexpressed receptors at lung tumor site with a ligand functionalized drug delivery system is the current approach, and pulmonary administration could augment chemotherapeutic effect of the drug through localized administration, minimizing the off-target effects by retention of the drug in lungs.Quercetin (QR), a natural flavonoid present in edible fruits and vegetables possess anticancer activity i.e. inhibits lung cancer growth. However, the application of QR in lung cancer therapy has been restricted by various factors i.e. low water solubility (2.15 µg/ml at room temperature), low bioavailability and rapid plasma clearance. To overcome the issues, we have formulated various QR-loaded liposomes surface functionalized with transferrin receptor (TFR) targeting peptides i.e. T7 (HAIYPRH) and T12 (THRPPMWSPVWP) in two research projects with active targeting ability, prolonged circulation time, and sustained release behavior for lung cancer specific QR delivery. In first research project, T7 targeted liposomes with different peptide densities i.e. 0.5%, 1% and 2% and QR-lip (non-targeted) were formulated. TFRs are over expressed (~100 folds) in various cancers including lung cancer and have low expression in most normal cells. T7 surface-functionalized liposomes (2% T7-QR-lip) demonstrated significantly enhanced cytotoxicity (~3-folds), cellular-uptake, S-phase cell cycle arrest and apoptosis in A549 cells. However, in MRC-5 (normal-lung fibroblast) cells no significant difference was observed after treatment with T7-QR-lip and QR-lip in cytotoxicity and cellular uptake studies. In tumor spheroid penetration and inhibition studies, T7 targeted liposomes showed deeper penetration and pronounced inhibition. In vivo biodistribution study via pulmonary administration of T7-DiR-lip has demonstrated liposomes accumulation in the lungs and sustained-release behavior upto 96h. Further, T7-QR-lip significantly enhanced anticancer activity of QR and life-span of orthotopic lung-tumor bearing mice (**p < 0.01, compared with control) via pulmonary administration. In second research project, T12 surface-functionalized liposomes with 0.5%, 1% and 2% T12 peptide densities and QR-lip have been formulated with ~95 % encapsulation efficiency. In vitro drug release study showed sustained release of QR from T12-QR-lip and QR-lip. In vitro experiments showed A549 cells treatment with 2% T12-QR-lip enhanced cellular-uptake, in vitro cytotoxicity, induced apoptosis and S-phase cell cycle arrest due to TFR mediated endocytosis. No significant variation has been observed in cellular-uptake and cytotoxicity after MRC-5 cells were treated with T12-QR-lip and QR-lip. Further, T12-Cou6-lip showed significantly deeper penetration i.e. 120 µm in 3D lung tumor-spheroids. Biodistribution study showed retention of T12-DiR-lip and DiR-lip mainly in the lungs upto 96h after pulmonary administration, as compared to free DiR. Pulmonary administration of T12-QR-lip showed the strongest tumor growth inhibition and survival time of orthotopic lung tumor implanted mice without any systemic toxicity as compared to QR-lip and free-QR. In summary, in vitro and in vivo results of the two research projects suggest that surface functionalization of the liposomes with TFR targeting peptides i.e. T7 and T12 is a promising approach for lung cancer therapy through active targeting and receptor mediated endocytosis of QR at lung tumor site. Moreover, T7 and T12 functionalized liposomes provides a potential drug delivery system for a range of anticancer drugs to enhance their therapeutic efficacy by localized i.e. pulmonary administration and targeted delivery.
APA, Harvard, Vancouver, ISO, and other styles
9

KALAJA, ODETA. "Nanoparticles based delivery System of Flavonoids for Cancer Therapy." Doctoral thesis, Università degli Studi di Trieste, 2018. http://hdl.handle.net/11368/2917683.

Full text
Abstract:
Nowadays, cancer remains one of the major public health problem. Although chemotherapeutic drugs efficiently kill cancer cells, these cells can defend themselves from such toxic compounds with a process called cancer multidrug resistance (MDR). Because of unsatisfactory treatment scenario there has been growing interest in the health advantages of using plant-derived compounds for cancer prevention or in the treatment of chemo-resistant cells. Anthocyanidins are a group of pigments belonging to the family of flavonoids present in red-blue fruits and vegetables. Several studies demonstrated that, together with their glycosylated forms, they exert intense biological activity towards normal and cancer cells, including selective cytotoxicity, capability to interact with extrusion pumps, cell cycle perturbation, anti-proliferation and apoptosis. Usually, the concentrations used to prove the biological effects of such compounds are far from those obtained when the assumption passes only through the ingestion of food rich of phytochemicals, and there is a lack of information on the possible long term toxic effects.
 Beyond proven biological effect, anthocyanins have low stability and bioavailability. Moreover, when ingested, their bioavailability is drastically reduced by their poor chemical stability in the weak alkaline conditions of the small intestine, thus challenging the possibility to translate their proven biological effects into therapeutic applications. Nanotechnologies has been widely applied in pharmaceutical field to improve the absorption of bioactive compounds. Delphinidin, one of the major anthocyanidins naturally found in red-blue fruits and vegetable, is a compound that exhibits a wide range of biological activities such as anti-tumor and anti-inflammatory and exert great effect on oxidative stress. In this study, we aimed to: a) Evaluate the effects of a non-toxic long-term treatment with delphinidin on LoVo/Dx cells (metastatic human colorectal adenocarcinoma cell line, doxorubicin resistant). Precisely, we studied the interferences with cell cycle, the expression of specific membrane transporters responsible for drug resistance, the accumulation of the drug in the cells, its cytotoxicity and the cellular ATP levels after treatment. Significant results, like cell cycle arrest and increase of doxorubicin accumulation were reported, but they were not linked to a down regulation of protein and ATP levels. Since these effects were not maintained in time, we hypothesized that the failure in chronic treatment with delphinidin could be attributable to adaptive metabolic response. Moreover, the low stability of the molecule in aqueous solution, such as culture media, suggested a higher suitability of action in acute conditions. b) Produce and assess different chemical and biological properties of Delphinidin-nanoparticles (DNPs) on biological samples. In particular, Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS) were used to measure size, dispersity and morphology. The encapsulation of delphinidin within chitosan nanoparticles was investigated through UV Resonant Raman Spectroscopy. The encapsulation efficiency of the nanoparticles was determined to be 73%, and their stability was strongly increased in comparison to the free compound. Results indicated that the DNPs are positively charged and are, therefore, an ideal carrier on targeting the colon mucosa. On different colon cancer cell lines, the DNPs treatment showed a dramatic increase of doxorubicin uptake in doxorubicin-resistant colon cells (LoVo/DX). In addition, preliminary results showed even a combined reduction of the expression of inflammatory biomarkers. In conclusion, these results show the higher performance of DNPs for applications in cancer drug development and might give rise to a new antitumor therapeutic approach avoiding cancer multidrug resistance.
APA, Harvard, Vancouver, ISO, and other styles
10

Cheng, Yu. "Gold Nanoparticles as Drug Delivery Vectors for Photodynamic Therapy of Cancers." Case Western Reserve University School of Graduate Studies / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=case1301503263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Drug delivery in cancer therapy"

1

Brown, Dennis M. Drug Delivery Systems in Cancer Therapy. New Jersey: Humana Press, 2003. http://dx.doi.org/10.1385/1592594271.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

L, Domellöf, ed. Drug delivery in cancer treatment. Berlin: Springer-Verlag, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Razelle, Kurzrock, and Markman Maurie, eds. Targeted cancer therapy. Totowa, N.J: Humana Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Feng, Tao, and Yanli Zhao. Nanomaterial-Based Drug Delivery Carriers for Cancer Therapy. Singapore: Springer Singapore, 2017. http://dx.doi.org/10.1007/978-981-10-3299-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hybrid nanostructures in cancer therapy. Hauppauge, N.Y: Nova Science Publishers, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

missing], [name. Tumor targeting in cancer therapy. Totowa, NJ: Humana Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Senter, Peter, Felix Kratz, and Henning Steinhagen. Drug delivery in oncology: From basic research to cancer therapy. Weinheim: Wiley-VCH, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gutiérrez, Lucía M. Neuro-oncology and cancer targeted therapy. New York: Nova Biomedical Books, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

M, Amiji Mansoor, ed. Nanotechnology for cancer therapy. Boca Raton: CRC/Taylor & Francis, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kumar, C. S. S. R., ed. Nanomaterials for cancer therapy. Weinheim: Wiley-VCH, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Drug delivery in cancer therapy"

1

Alexis, Frank, Eric M. Pridgen, Robert Langer, and Omid C. Farokhzad. "Nanoparticle Technologies for Cancer Therapy." In Drug Delivery, 55–86. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-642-00477-3_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alley, Stephen C., Simone Jeger, Robert P. Lyon, Django Sussman, and Peter D. Senter. "Empowered Antibodies for Cancer Therapy." In Drug Delivery in Oncology, 289–323. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sankar, Renu, V. K. Ameena Shirin, Chinnu Sabu, and K. Pramod. "Carbon Nanotubes in Cancer Therapy." In Drug Delivery Using Nanomaterials, 287–309. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003168584-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhu, Zhenping, and Daniel J. Hicklin. "Antibody-Mediated Drug Delivery in Cancer Therapy." In Cellular Drug Delivery, 311–44. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-745-1_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Yhee, Ji Young, Sejin Son, Sohee Son, Min Kyung Joo, and Ick Chan Kwon. "The EPR Effect in Cancer Therapy." In Cancer Targeted Drug Delivery, 621–32. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7876-8_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Matsumura, Yasuhiro, Masahiro Yasunaga, and Shino Manabe. "Cancer Stromal Targeting (CAST) Therapy and Tailored Antibody Drug Conjugate Therapy Depending on the Nature of Tumor Stroma." In Cancer Targeted Drug Delivery, 161–81. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7876-8_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Barar, Jaleh, Yadollah Omidi, and Gumbleton Mark. "Molecular Targeted Therapy of Lung Cancer: Challenges and Promises." In Pulmonary Drug Delivery, 263–84. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118799536.ch12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Traore, Mahama A., Ali Sahari, and Bahareh Behkam. "Construction of Bacteria-Based Cargo Carriers for Targeted Cancer Therapy." In Targeted Drug Delivery, 25–35. New York, NY: Springer US, 2018. http://dx.doi.org/10.1007/978-1-4939-8661-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Xiao, Zeyu, Jillian Frieder, Benjamin A. Teply, and Omid C. Farokhzad. "Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy." In Drug Delivery in Oncology, 1263–81. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Burke, Thomas G., Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus. "Recent Advances in Camptothecin Drug Design and Delivery Strategies." In Camptothecins in Cancer Therapy, 171–90. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-866-8:171.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug delivery in cancer therapy"

1

Sinsuebphon, Nattawut, Alena Rudkouskaya, Margarida Barroso, and Xavier Intes. "Whole body lifetime FRET imaging in transmission and reflectance for the assessment of drug delivery efficacy in small animals." In Cancer Imaging and Therapy. Washington, D.C.: OSA, 2016. http://dx.doi.org/10.1364/cancer.2016.jm3a.48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Madhusudhanan, J., P. Arivazhagi, J. Balavignesh, and K. Sathish Kumar. "Invivo drug delivery for cancer therapy using gold nanoparticle." In International Conference on Advanced Nanomaterials & Emerging Engineering Technologies (ICANMEET-2013). IEEE, 2013. http://dx.doi.org/10.1109/icanmeet.2013.6609399.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Inai, Mizuho, Masaya Yamauchi, Norihiro Honda, Hisanao Hazama, Shoji Tachikawa, Hiroyuki Nakamura, Tomoki Nishida, Hidehiro Yasuda, Yasufumi Kaneda, and Kunio Awazu. "Hemagglutinating virus of Japan envelope (HVJ-E) allows targeted and efficient delivery of photosensitizer for photodynamic therapy against advanced prostate cancer." In Optical Molecular Probes, Imaging and Drug Delivery. Washington, D.C.: OSA, 2015. http://dx.doi.org/10.1364/omp.2015.om2d.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chizenga, Elvin Peter, and Heidi Abrahamse. "Enhancing Photodynamic Therapy of Cancer by Intracellular Delivery of Photosensitizer." In Frontiers in Optics. Washington, D.C.: Optica Publishing Group, 2022. http://dx.doi.org/10.1364/fio.2022.jtu5a.67.

Full text
Abstract:
Immunogenic proteins in cancer are relevant targets for drug delivery. A multifunctional photo-activating compound directed to such proteins was developed for Photodynamic Therapy of Human Papillomavirus-transformed cancer cells. Selective binding increased therapeutic efficacy by two-folds.
APA, Harvard, Vancouver, ISO, and other styles
5

Weerathunga, Dulanga, and Koshala Chathuri De Silva. "NANOTECHNOLOGY BASED TARGETED DRUG DELIVERY SYSTEMS IN BREAST CANCER THERAPY." In International Conference on Bioscience and Biotechnology. The International Institute of Knowledge Management (TIIKM), 2017. http://dx.doi.org/10.17501/biotech.2017.2105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rajeswari, N. Raja, and P. Malliga. "Microfluidic system using microneedles for targeted drug delivery in cancer therapy." In 2013 IEEE International Conference on Smart Structures and Systems (ICSSS). IEEE, 2013. http://dx.doi.org/10.1109/icsss.2013.6623000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sorace, Anna G., Reshu Saini, Marshall J. Mahoney, and Kenneth Hoyt. "Targeted molecular ultrasound therapy improves chemotherapeutic drug delivery in cancer cells." In 2012 IEEE International Ultrasonics Symposium. IEEE, 2012. http://dx.doi.org/10.1109/ultsym.2012.0106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Aili, Xipeng Mi, and Lisa X. Xu. "Study of Thermally Targeted Nano-Particle Drug Delivery for Tumor Therapy." In ASME 2008 First International Conference on Micro/Nanoscale Heat Transfer. ASMEDC, 2008. http://dx.doi.org/10.1115/mnht2008-52383.

Full text
Abstract:
The efficacy of cancer chemotherapeutics could be greatly enhanced by thermally targeted nanoparticle liposome drug delivery system. The tumor microvasculature response to hyperthermia and its permeability to the nano-liposomes were studied using the 4T1 mouse model and confocal fluorescence microscopy. Based on the experimental results, a new theoretical model was developed to describe the distributions of both the liposomal and free drug released as liposomes broke in tumor for treatment evaluation. In this model, the tumor was divided into two regions: peripheral and central. The drug effect on the tumor cell apoptosis and necrosis was considered. Upon the experimental validation, the model was used to simulate drug distribution in the tumor under either the hyperthermic or the alternate freezing and heating condition. Results showed that hyperthermia alone only enhanced drug accumulation in the tumor periphery and therefore more serious tumor damage induced in the region. But the tumor cells in the central region were hardly damaged due to the lack of drug diffusion. The alternate freezing and heating was proposed to aid the nanoliposomal drug delivery, and better results were found.
APA, Harvard, Vancouver, ISO, and other styles
9

Singh, Rajesh, Shailesh Singh, Guru P. Sonpavde, and James W. Lillard. "Abstract 5531: Combination drug delivery using PBM nanoparticle to improve prostate cancer therapy." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hasan, Tayyaba. "Spatiotemporally synchronized cancer combination therapy using photo-activated nanoparticle drug delivery systems (Conference Presentation)." In Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXV, edited by David H. Kessel and Tayyaba Hasan. SPIE, 2016. http://dx.doi.org/10.1117/12.2217533.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Drug delivery in cancer therapy"

1

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2002. http://dx.doi.org/10.21236/ada410175.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada435264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Esenaliev, Rinat O. Novel Drug Delivery Technique for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada418735.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Band, Hamid, Srikumar Raja, and Tatiana Bronich. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada577110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bronich, Tatiana, Hamid Band, and Srikumar Raja. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2013. http://dx.doi.org/10.21236/ada580965.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Band, Hamid, and Tatiana Bronich. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2014. http://dx.doi.org/10.21236/ada599969.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bronich, Tatiana, and Hamid Band. Mechanism-Based Enhanced Delivery of Drug-Loaded Targeted Nanoparticles for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, February 2014. http://dx.doi.org/10.21236/ada600027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Paul C. A Partnership Training Program: Studying Targeted Drug Delivery Using Nanoparticles in Breast Cancer Diagnosis and Therapy. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada613187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wang, Paul C. A Partnership Training Program: Studying Targeted Drug Delivery Using Nanoparticles in Breast Cancer Diagnosis and Therapy. Fort Belvoir, VA: Defense Technical Information Center, October 2012. http://dx.doi.org/10.21236/ada568802.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Paul C. A Partnership Training Program: Studying Targeted Drug Delivery Using Nanoparticles in Breast Cancer Diagnosis and Therapy. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada597692.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drug delivery in cancer therapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography